Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide plus ADT vs placebo plus ADT in high-risk biochemical recurrence of prostate cancer
jRCT2051230094Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide + ADT with Placebo + ADT (2 arms). Primary endpoint: Radiological progression-free survival (rPFS) by PSMA PET/CT. Started Feb 2024; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2051230094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230094.